# CTx-1301 Comparative Bioavailability Study

> **NCT04138498** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cingulate Therapeutics** · enrollment: 45 (actual)

## Conditions studied

- ADHD

## Interventions

- **DRUG:** Dexmethylphenidate 5 Mg Oral Capsule, Extended Release
- **DRUG:** Dexmethylphenidate 6.25 mg Tablet
- **DRUG:** Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
- **DRUG:** Dexmethylphenidate 50 mg Tablet

## Key facts

- **NCT ID:** NCT04138498
- **Lead sponsor:** Cingulate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-06
- **Primary completion:** 2020-03-06
- **Final completion:** 2020-03-06
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04138498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04138498, "CTx-1301 Comparative Bioavailability Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04138498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*